This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

chad:
Indeed it is fairly cheap below 200p and could bounce here back to 220p in a few days..

By the way, where has Goldfinger got to these days?

Mickey Skint - Must have been that curry you had last night?

B

Got this from the other place. Good points.

THE CENTRAL QUESTION: IS MMI A BIT SPECIAL?

Technical analysts and shorters and generally those who think this has come too far to fast point to other companies such as Oxford Bio and Alizyme which had a spike but fell from there.

But is MMI a bit special?

The chart of Glaxo was pretty much up and up and up...

MMI has a drug which is seeking to replace the BIGGEST SELLING CANCER DRUG TO DATE. It has a high chance of doing this as it is very similar to the existing drug and because the inventor of the previous drug sought to join the team. This is blockbuster with a capital B.

Apart from the fact that MMI have a great business model, have achieved something with Genvax and DNA cancer vaccines that others have faied to acheive for 20 years. This potential in Ruthenium just makes the shares plain cheap to me.

MMI will soon have more potential blockbuster drugs in the clinics than major pharma companies such as Astra Zeneca.

I am long and my view is that MMI is indeed a bit special.

Slap

An other good one. The boys on the other side can be sensible when they want to.

On the subject of valuations (and I'm probably not telling you much you don't already know) from a financial perspective, a theoretically correct approach would be:
-forecast sales for the drug (if successful) over the life of the patent
-multiply this forecast by the percentage royalty rate: I believe someone on this thread said 20-30%. These are cash flows accruing to the IP holder.
-discount these back to their present value, using the cost of capital for a large pharamcetical company or market sector. This is the value of the drug right now.
-multiply this by the probability of bringing the drug successfully to the market.
This should be the current market value of the drug.
Doing this exercise for Oncosense, using pessimistic assumptions, gave me a value of 3 per share for MMI. If you relax the assumptions you start to get numbers which are difficult to believe.

Incidentally, my impression is that it is a foregone conclusion that Oncosense will go into clinical trials.

...coming back nicely now - time to catch that knife?

Tomorrow is the last day for CGT allowances, so wouldn't be surprised if the shorters had another pop.

MS

Even it was a lot higher when I got in, but I feel like gaining now. Wish more buyers tomorrow.

Anyone here get Small Company Sharewatch? Recently subscribed and just wondered when the next issue is due?

Yes Chad i do it comes in the middle of the month always on a saturday,,due in a couple of weeks ..JB..

Tecnically we a due a bounce after yesterdays strong performance...230p should be a support.

On the rise.... fairly tight spread, we will see day traders in and out.
Consolidation at 230 would be nice mitzy.
rob

Up we go..higher & higher. MM's can have mine for 5.

MS

lol...make it 2000p mickey..

Cheers JB.

how high it could go by this wkend? any prediction? many thanks.

swseun,,,,, what we need now is a period of stability...... if we get another upward surge with no real news it will just be shorted back down again. I would like to see 250 again by the end of the week and then some small tick ups during the next few weeks before the coming news..... which we hope will be positive

many thanks rob308, it seems profit taking still there but not a lot, they may got in @ 200p and selling now for quick pofit. any suggestion? and would be nice if 250p end this week. But if above 3 by end this month, it is great.

I think 300 by the end of this month is quite possible. This stock has now come to the attention of the day traders so we will see increased volatility in general. However this should not distract from the incredible potential of this company with its numerous different products at various stages of R&D.
It really is a matter of if you have any spare cash pick a few up as and when you can, there is also the strong possibility of mmg being targeted for a takeover (IMHO) BY ONE OF THE BIG PHARMA'S.

the steady rise today rather make me happy. :-) I agree that it is worth to buy more. Depends on the open price tomorow morning, comparing to the buy/sell volumn today may give me an idea. Of course I may be worng.